African Journal of Biotechnology
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
African Journal of Biotechnology Vol. 2 (7), pp. 189–193, July 2003 ISSN 1684-5315 © 2003 Academic Journals
Full Length Research Paper Efficacy of IgG, Fab, and F(ab')2 fragments of horse antivenom in the treatment of local symptoms after Cerastes cerastes (Egyptian snake) bite Salwa
S. Abdel Latif1*, Soheir Wanas1, George Abdel Malak1 and Madiha H. Helmy2
1Egyptian Organization for Biological Products and Vaccines (VACSERA), 51 Wezaret Elzeraa St., Agouza, Giza 2Biochemistry Research Institute,
Alexandria university, 165 ElHoria Road, El-Hadra
region , Egypt. *Corresponding
author: E-mail: salwaseddik@hotmail.com,
Fax: (+202) 3369872-7483187-7609177 |
|||||||||
| Abstract | ||||||||||
|
|
The ability of horse antivenoms, consisting of immunoglobulin G (IgG) and its fragments F(ab')2 and Fab were comparatively studied in mice to neutralize several effects of Cerastes cerastes venom. The three antivenoms were produced from the same batch of hyperimmune horse plasma. Neutralization was only partial when antivenins were administered intravenously at various time intervals after envenomation. No significant differences were observed among IgG, Fab, and F(ab')2 antivenoms concerning neutralization of hemorrhagic effects. Fab fragments were slightly more effective in neutralizing edema while IgG and F(ab')2 antivenoms were better in neutralizing myonecrosis in experiments involving independent injection of venom and antivenom.Thus these results disagree with the theory that "Fab " fragments are more effective than whole IgG and F(ab')2 in the neutralization of local symptoms accompanying C. Cerastes venom. Key words: Cerastes cerastes, Egyptian snake, IgG, F(ab')2, Fab.
|
||||||||
| Introduction | ||||||||||
|
Various local tissue alternations accompanying snakebite such as hemorrage, edema and myonecrosis, may result in tissue loss or organs dysfunction (Ownby, 1982; Gutierrez, 1995). These effects develop very rapidly after snake envenomation, making neutrlization by antivenoms very difficult, especially if serotherapy is delayed due to either late access to medical care or scarcity of antivenoms (Gutierrez et al., 1998). In the anti-sera production plant of VACSERA (Egyptian Organization for biological products and Vaccines) antivenoms have been produced by fractionation of hyperimmune horse plasma in order to obtain either immunoglobulin G (IgG) or F(ab')2 fragments (Raw et al., 1991; Pope et al., 1939) which was modified by (Grechushkina-Sukhorukova et al., 1984). It has been postulated that Fab fragments, obtained by papain digestion of immunoglobulins, may constitute a more convenient therapeutic tool (Dart and Horowitz, 1996). Various Fab antivenins have been produced (Laing et al., 1995; Landon and smith, 1996) and some have been evaluated in clinical trials (Karlson- Stiber et al., 1997; Meyer et al., 1997). Two theoretical advantages of Fab fragments are their wide volume of distribution, and their ability to reach tissue compartment at a faster rate when compared to IgG and F(ab')2 preparations (Covell et al., 1986; Scherrmann, 1994). These two pharmacokinetic characteristics would be of value in the neutralization of locally-acting toxins, since Fab fragments might be able to reach and neutralize toxins present in the tissue more readily than whole IgG and F(ab')2. The present study tested this hypothesis by comparing the ability of horse whole IgG, Fab and F(ab')2 fragments antivenoms to neutralize local hemorrage, edema and myonecrosis induced by C. Cerastes venom in mice.
|
|||||||||
| Materials and Methods | ||||||||||
|
Venom and hyperimmune
plasma The venom used in this work was obtained from C. Cerastes snakes
collected in Helwan farm of the Egyptian Organization for biological
products and Vaccines (VACSERA). Once obtained, the venom was lyophilized
and stored at -20ºC until used. Plasma was collected from horses that had
been immunized with the venom of C. Cerastes with increasing doses
as discribed by Estrada et al. (1992). Preparation of
antivenoms Fractionation of IgG: To
obtain whole IgG, plasma was fractionated by caprylic acid precipitation
according to (Rojas et al., 1994). Briefly caprylic acid is added drop
wise directly to undiluted plasma whose pH has been adjusted to 5.8 by the
addition of 1.76 N acetic acid. Caprylic acid was added up to a final
concentration 5% ( v/v) followed by vigorous stirring for one hour at room
temperature before filtration. The mixture was filtered through Whattman
filter K300 followed by EKS2
respectively. The filtrate was dialyzed for 48 hours against phosphate
buffered saline (PBS) at pH 7.2 followed by ultrafilteration to remove
caprylic acid. Afterwards, NaCl and tricresole were added to a final
concentration of 0.15M and 0.35%, respectively. The preparation was
sterilized by filteration through 0.22-μm membranes. Purification of F(ab')2
fragments: F(ab')2 fragments
were prepared by pepsin digestion after adjusting the pH of plasma to 3.3
by 1.76N acetic acid followed by the addition of 3.5g pepsin/liter plasma.
Digestion was performed at 22-25ºC for 1 hour, and the pH was elevated to
3.6 using 1N NaOH for 30 min. Afterward plasma pH was readjusted to 5.8
and the mixture was incubated for 15 min. at 56ºC followed by
centrifugation for 10 min. at 900 x g to remove fibrinogen. Caprylic acid
was added dropwise to the undiluted plasma to attain a final concentration
of 5% (v/v). The mixture was stirred vigorously for 24 h, followed by the
same extraction and purification steps as previously stated for IgG
preparation (Dos Santos et al., 1989) Purification of Fab fragments: Fab antivenom was
obtained by adjusting the pH of plasma to 7 followed by addition of 20 g/l
papain and 1g/l cysteine. Digestion was performed at 22-25ºC for 2 hours,
and caprylic acid was added to attain a final concentration of 5% (v/v).
The mixture was vigorously stirred during 24 h, and then filtered. The
filtrate was dialyzed against PBS and sterilized by filtration through
0.22 μm membrane, after the
addition of 0.15 M NaCl and 0.35 % tricresol as described by Leon et al. (2000). The three-antivenin preparations were adjusted to have the same
neutralizing potency (75 U/ml) against C. cerastes to ensure that
if variations arise in experiments with independent injection of venom and
antivenoms, they would be due to the pharmacokinetic profile of the
products and not to differences in their ED50. It was demonstrated in a previous preliminary studies that ED50 (75
U/ml) could completely
abolish these previously mentioned symptoms after snakebite in experiments
in which venom and antivenoms were incubated prior to injection (VACSERA
research). Neutralization studies Neutralization of hemorrhage: In experiments with independent injection of venom and antivenoms,
groups of four swiss albino mice (20-22g) were initially injected
intradermally with 0.1ml PBS containing 25 μg
of venom/mouse in the abdominal region. At various time intervals (0, 10,
20 and 30 min), 0.2 ml of each antivenom was administered intramuscularly
in the right gastrocnemius. Hemorrhage was assessed in the skin 2 h after
venom injection. The mice were sacrificed, their skin removed and the
hemorrhage area measured. Control mice were injected with the same amount
of venom without antivenom as described by Gutierrez et al. (1985). Neutralization of edema: Groups of four mice (20-22 g) were injected in the right foot pad with
10 μg
venom dissolved in 50 μl of PBS, whereas the left foot pad received 50 μl of PBS alone. Then
0.2 ml of either native IgG, Fab or F(ab')2
fragments were
administered intravenously immediately or after 15, and 30 min). Control
mice received 10 μg
venom only. Edema was assessed one hour after envenomation. The mice were
sacrified by cervical dislocation, and their feet were cut and weighed.
Edema was expressed as percentage of increment in the weight of the right
foot as compared to the left one (Gutierrez et al., 1986). Neutralization of myotoxicity: The method of Gutierrez et al. (1981) was followed. Groups of four mice
were injected intramuscularly with 25 μg
venom in the right gastrocnemius at different time intervals (0, 20 and 40
min.), and 0.2 ml of either IgG or Fab and F(ab')2
antivenoms were administered intravenously. Control mice were injected with
venom alone. Plasma creatine kinase activity was assessed 3 h after venom
injection. Blood samples were collected from the tail into heparinized
tubes, and plasma creatine kinase activity was determined by the Sigma kit
No. 520. Creatine kinase activity was expressed as units/ml, one unit
resulting in the phosphorylation of one nanomole of creatine/min at 25ºC.
|
|||||||||
| Results | ||||||||||
|
Neutralization of haemorrhagic activity When antivenoms were administrated intramuscularly at different time intervals after venom injection, only partial neutralization was achieved. Figure 1 shows that Fab give the better neutralizing activity than F(ab')2 and IgG. All the three antivenoms gives better results when administered immediately after envenomation.
Figure 1. Neutralization of hemorrhagic effect induced by C. cerates venom after administration of Fab, F(ab')2 and IgG antivenoms in experiments involving independent injection of venom and antivenom. Control mice were injected with venom alone having as much as 100% hemorrhagic effect.
Neutralization of edema Fab salso gave the better results in neutralizing edema in experiment where antivenoms were administered intravenously after envenomation. While F(ab')2 and IgG showed similar neutralizing activity (Figure 2).
Figure 2. Neutralization of edema induced by C. cerates venom after administration of Fab, F(ab')2 and IgG antivenoms in experiments with independent injection of venom and antivenom. Edema is expressed in percentage, with as much as 100% effect induced by venom alone. Edema was assessed 1 h after venom injection.
Neutralization of myonecrosis Mice injected with venom alone had plasma creatine kinase activity of 920±37.7 units/ml, whereas activity of plasma from mice receiving PBS alone was 64.4±4.3 units/ml. When antivenoms were injected after venom, neutralization of myotoxicity was only partial even in conditions where immunotherapy was performed immediately after envenomation (Figure 3). IgG and F(ab')2 antivenoms showed better neutralizing ability at all times tested than Fab.
Figure 3. Neutralization of myonecrosis induced by C. cerates venom after administration of Fab, F(ab')2 and IgG antivenoms in experiments with independent injection of venom and antivenom. Myonecrosis was assessed 3 h after venom injection by quantitating plasma creatine kinase (CK) activity. Myonecrosis is expressed in percentage, with as much as 100% effect induced by venom alone. |
|||||||||
| Discussion | ||||||||||
|
Despite the recent marked improvement in the field of immunoglobulins
structure and function, the resulting knowledge has not been fully applied
to antitoxin or antivenin production (Morais et al., 1994). However
antivenoms are considered to be the mainstay in the treatment of snakebite
envenomation (Dart and Horowitz, 1996) because of their efficacy in
neutralizing systemically acting toxins. Nevertheless, clinical evidence
indicates that they are only partially effective in neutralizing venom
induced local tissue damage (Gutierrez et al., 1998). This was the
motivation for carrying out the present study. IgG and its fragments F(ab')2
and Fab were produced
and purified using caprylic
acid method, which eliminate irrelevant plasma proteins such as albumin
and fibrinogen. Such purified preparation is devoid of undesirable
effects, like anaphylactic, attacks induced by the eliminated irrelevant
proteins (Morais et al., 1994). For proper comparison among the antivenoms, their doses were
standardized to have the same neutralizing potency against venom when
incubated together before injection. It can therefore be assumed that any
variations in neutralization capability would then be due to differences
in the pharmacokinetics profiles of the preparations. In the present
study, the time factor (time of injecting the antivenom) was very
critical. Although the neutralizing capacity at all time points was only
partial, the sooner the treatment was applied, the more pronounced was the
neutralizing effect for all parameters tested. With longer delays in
treating the victim with antivenin, the values of the tested parameters
quickly approached the untreated control values. The cause of the partial
ineffectiveness of antivenoms is probably related to rapid development of
local effect after envenomation, therby precluding neutralization
(Gutierrez et al., 1985) or probably due to relatively inadequate
antivenom dose, but not the absence of neutralizing antibodies in the
antivenom. Although Fab did not show good activity to counteract myonecrosis
produced by C. cerastes venom, as measured by release of creatine
kinase into the blood, it ranked first among the three tested preparations
in the other two parameters; namely hemorrhage and edema formation. This
is probably because Fab is less immunogenic compared to IgG and F(ab')2.
Moreover, Fab has a relatively more favorable pharmacokinetic profile with
its lower molecular weight and larger volume of distribution, together
with its ability to reach the tissue compartment at a faster rate. This,
unfortunately, is coupled with rapid renal clearance, which may decrease
the tissue concentration of Fab. Such unfavorable property may be offset
by the presumption that Fab molecules may have greater association with
cellular material (Scherrmann, 1994; Riviere, 1997). On the other hand,
IgG and F(ab')2 with
their higher molecular weights and shorter diffusion rates may be more
localized in the tissues where toxins are present . The differences in
diffusion rates may be more localized in the tissues where toxins are
present. Therefore, the differences in diffusion into blood and tissue
compartments may explain the difference in action on hemorrhage and
myonecrosis. It should not be expected, however, that Fab or any of the
other antivenom fractions, can completely counter act the hemorrhagic
activity of the venom. Perez et al. (1984) claimed that hemorrhagic
factors have several antigenic determinants and that it is unlikely that a
single antibody could neutralize the hemorrhagic completely. The rapid decrease in the ability of the antivenom fractions to
neutralize toxins with time should be seriously considered. This may be
due to the extremely rapid sequence of toxic events and the development of
local tissue damage following envenomation (Gutrierrez et al., 1980;
Moreira et al., 1992; Lomonte et al., 1994; Chaves et al.,
1995). An
important factor is the time lapse between envenomation and serotherapy.
The speed with which the antivenom binding in the circulation and
redistribution of the toxins from the tissues into circulation are
important factors (Choumet et al., 1996; Riviere et al.,
1997). A proper
study of toxin and antivenom kinetics in the victim is therefore
mandatory. It has been reported (Morais et al., 1994) that when IgG or F(ab')2
is used for the
treatment of envenomation, they can equally induce anaphylactic shock
through complement activation by classical and alternative pathways. Fab,
however, does not induce anaphylaxis because it has only one binding site
and does not cross-link to form immune complexes (Morais et al.,
1994).
This gives an advantage to Fab preparations, which may be administered in
consecutive multiple doses to compensate for its rapid renal clearance
because of its relatively low molecular weight. The relatively low
toxicity accompanied with the use of Fab points to its possible successful
use at higher dose levels without deleterious effects. The search should
also be directed toward identifying an antivenin preparation that can
better neutralize locally acting toxins as well. Finally, we assert that neutralization of toxin in tissue is negligible
in the studies involving separate injection of venom and antivenom at
different intervals of time. This is may be due to the extremely rapid
development of local tissue damage, edema, myonecrosis and hemorrhage
within minutes after injection of venom (Gutierrez et al., 1980,
1984;
Lomonte et al., 1994; Chaves et al., 1995). Furthermore, there is always a
time lapse between envenomation and serotherapy. Thus, the most important
mechanism is the antibody toxins binding in the circulation, with
consequent redistribution of the toxins from the tissue to the circulation
(Choumet et al., 1996; Riviere et al., 1997). In conclusion when IgG or F(ab')2
is used in the
treatment of envenomation there was no differences in neutralization. Both
can equally induce anaphylactic shock through complement activation by
classical or alternative pathway (Morias et al., 1994). Fab preparation
can be administered with multiple doses to compensate for its rapid
clearance through the kidney due to its low molecular weight. And since
Fab has only one binding site and do not cross link to form immune
complexes, its low toxicity makes it possible for its use at higher
concentrations than the other products tested, without deleterious
effects. Thus the production of antivenom that includes IgG and its
fragments, F(ab')2 and
Fab, is necessary to treat the
local symptoms. Trials are underway to determine the addition of natural
substances to the immune-sera to treat snakebite including neutralization
of the local-acting toxins. ACKNOWLEDGMENT The authors are grateful to the chairman of VACSERA. Prof.Dr.Mohamed El-Abbadi
for his generosity and kindness in supporting this work. | |||||||||
| References | ||||||||||
|
Chaves F, Borboza M, Gutierrez JM (1995). Pharmacological study of oedema induced by venom of the snake Sanitaria. Panamericana 88:184-196. Choumet V, Audebert F,
Riviere G, Sorkine M, Urtizberea M, Sabouraud A, Scherrmann JM, Bon C
(1996). Toxicokinetics of vipra aspts in venpming and antivenom therapy,
In; Bon. C. Goyffon, M. (Eds), envenomings and their treatments. Edition
fondation Marcel Merieux. Lyon. pp. 127-133. Covell DG, Barbet J, Holton
OD, Black CDV, Parker RJ, Weistein JN (1986). Pharmacokinetics of
monoclonal immunoglobulin G1. F(ab')2
Fab in mice. Cancer
Res. 46: 3969- 3978. [Pubmed] Dart RC, Horowitz RS (1996). Use of antibodies as antivenoms: a
primitive solution for a complex problem? In: Bon C, Goyffon M (Eds.).
Envonoming and their treatments. Editions Fondation Marcel Merieux. Lyon,
pp. 83-94. Dos Santos MC, Dimperio-Lima MR, Furta GC, Colleto GMDD, Kipnis TL, Dias
Da Silva W (1989). Purification of F(ab')2 anti-snake
venom by caprylic acid: A fast method for obtaining IgG fragments with
large neutralization activity, purity and yield. Toxicon. 27: 297-303.
[Pubmed] Estrada R, Chaves F, Robles A, Rojas E, Gutierrez JM (1992). Valores
Hematologicos y de enzymas sericas en caballos inoculados con venenos
de Serpients para la produccion de antivenenos en Costa Rica. Rev.
Biol. Trop. 40: 95-99. [Pubmed] Grechushkina-Sukhorukova VA, Telbukh VP, Stepepanov VM (1984).
Proteolysis of horse blood serum proteins at various stages of antitoxic
sera production by the Diaferm-3-Method. Prikl. Biokhim. Mikrobiol. 20:
528-533. [Pubmed] Gutierrez JM, Arroyo O, Balanos R (1980). Mionecrosis,hemorragia y edema
inducidos por el veneno de Bothrops asper en ratio blanco. Toxicon.
18:603-610. [Pubmed] Gutierrez JM, Chaves F, Bolanos R, Cerdas L, Rojas e Arroyo O, Portilla
E (1981). Neutralizacion de los efectos locales del veneno de Bothrops
asper por un antiveneno polivalente.Toxicon. 19:493-500. [Pubmed] Gutierrez JM, Ownby CL, Odell GV (1984). Pathogenesis of myonecrosis
induced by crude venom and a myotoxin of Bothrops asper. Exp. Mol. Pathol.
40: 367-379. [Pubmed] Gutierrez JM, Gene JA, Rojas G, Cerdas L (1985). Neutralization of
proteolytic and haemorrhagic activities of Costa Rican snake venoms by a
polyvalent antivenom. Toxicon. 23: 887-893. [Pubmed]
Gutierrez JM, Rojas G, Lomonte B, Gene JA, Cerdas L
(1986). Comparative
study of the oedema-forming activity of Costa Rican snake venoms and its
neutralization of a polyvalent antivenom. Comp. Biochem. Physiol. 85C:
171-175. [Pubmed] Gutierrez JM (1995). Clinical toxicology of snake bite in central
America. In: Meier. J., White, J. (Eds), Handbook of clinical toxicology
of animal venoms and poisons. CRC Press. Boca Raton, Fl. Pp. 645-665. Gutierrez JM, Leon G, Rojas G, Lomonte B, Rucavado A, Chaves F (1998).
Neutralization of ocal tissue damage induced by Bothrops asper (terciopelo)
snake venom. Toxicon. 36: 1529-1538. [Pubmed] Karlson-Stiber C, Presson H, Smith D, Al-abdulla IH, Sjostrom L (1997).
First clinical experiences with specific sheep Fab fragments in snake
bite. Report of a multicentre study of Vipera berus envenoming. J. Intern.
Med. 241: 53-58. [Pubmed] Landon J, Smith DC (1996). Development of novel antivenoms based on
specific ovine Fab. In: Bon, C., Goyffon, M. (Eds.), Envenomings and Their
Tratments. Editions Fondation Marcel Merieux, Lyon, pp. 173-180. Laing GD, Lee L, Smith DC, Landon J, Theakston RGD (1995). Experimental
assessment of a new, low-cost antivenom for treatment of carpet viper (Echis
ocellatus) envenoming. Toxicon 33, 307-313. [Pubmed] Leon G, Valverdo JM, Rojas G, Gutierrez JM (2000). Comparative study on
the ability of IgG and Fab sheep antivenoms to neutralize local
hemorrhage,oedema and myonecrosis induced by Bothrops asper snake venom.
Toxicon. 38: 233-244. [Pubmed] Lomonte B, Lundgren J, Johansson B, Bagge U (1994). The dynamics of local
tissue damage induced by Bothrops asper snake venom and myotoxin II on the
mouse cremaster muscles an intravital and electron microscopic study.
Toxicon. 32: 41-55. [Pubmed] Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Naidi A, Daudu IJ,
Warrell DA, Theakston RDG (1997). First clinical experiences with a new
ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized
comparative trial with Institute Pasteur serum (IPSER) Africa antivenom.
Am. J. Trop. Med. Hyg. 56: 291-300. [Pubmed] Morais JF, De Freitas MCW, Yamaguchi LK, Dos Santos MC, Dias Da Silva W
(1994). Snake antivenoms from hyperimmunized horses: Comparison of the
antivenom activity and biological properties of their whole IgG and F(ab')2
fragments. Toxicon.
32: 725-734. [Pubmed] Moreira L, Gutierrez JM, Borkow G, Ovadia M (1992). Ultrastructural
alternations in mouse capillary blood vessels after experimental injection
of venom from snake Bothrops asper. Exp. Mol. Pathol. 57: 124-133.
[Pubmed] Ownby CL (1982). Pathology of rattlesnake envenomation. In: Tu AT (Ed.).
Rattlesnake venoms. Their action and treatment. Marcel Dekker, New York.
Pp. 163-209. Perez JC, Garcia VE, Huang SY (1984). Production of monoclonal antibody
against hemorrhagic activity
of Crotatus atrox (Western diamonback rattlesnake) venom. Toxicon 22:967.
[Pubmed] Pope CG (1939). The action of proteolytic enzymes on antitoxins and protein in immune sera .I. True digestion of the proteins. Br. J. Exp. Path. 20: 132. Raw L.,Guidolin,R.,Higashi,H.G.and Kelen,E.M.A.(1991).Antivenin in
Brazil: Preparation. In: Handbook of Natural toxins,vol.5, Reptile venoms
and toxins pp. 557-581. (Tu,A.T.,Ed).New york:Marcel Dekker. Riviere G, Choumet V, Audebert F, Sabouraud A, Debray M, Scherrmann JM,
Bon C (1997). Effect of antivenom on venom pharmacokinetics in
expermentally envenomed rabbits: toward an optimization of antivenom
therapy. J. Pharmacol. Exp. Ther. 281: 1-8. [Pubmed] Rojas G, Jimenez JM, Gutierrez JM (1994). Caprylic acid fraction of
hyperimmune horse plasma: Description of a simple procedure for antivenom
production. Toxicon. 32: 351-363. [Pubmed] Scherrmann JM (1994). Antibody treatment of toxic poisoning, recent
advances. Clin. Toxicol. 32: 363-375. [Pubmed] |
|||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |